A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients - the INSIGHT-MM study

Study identification

• EU PAS number:
  EUPAS41735
• Study ID:
  48872
• Official title and acronym:
  A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients - the INSIGHT-MM study
• DARWIN EU® study:
  No
• Study countries:
  Belgium

  Brazil

  China

  Colombia

  France

  Germany

  Greece

  Israel

  Italy

  Mexico

  Spain

  Taiwan

  Türkiye

  United Kingdom

  United States
• Study description:
  The purpose of this study is to describe contemporary, real-world patterns of patient characteristics, clinical disease presentation, therapeutic regimen chosen, and clinical outcomes in participants with newly diagnosed ND multiple myeloma (MM) and participants with relapsed/refractory R/R MM.
• Study status:
  Finalised

Research institutions and networks

Institutions

Takeda

Multiple centres: 134 centres are involved in the study

Study timelines

Date when funding contract was signed

Actual: 30/06/2016

Study start date

Actual: 01/07/2016

Data analysis start date

Actual: 03/07/2021

Date of final study report

Planned: 11/08/2022

Actual: 08/08/2022

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Takeda

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 2 (specific obligation of marketing authorisation)